Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1.
Cytochrome P-450 CYP3A
Immunosuppressive therapy
Inter-individual pharmacokinetic variability
Intra-individual pharmacokinetic variability
Narrow therapeutic index
Therapeutic drug monitoring
Journal
Microbiome
ISSN: 2049-2618
Titre abrégé: Microbiome
Pays: England
ID NLM: 101615147
Informations de publication
Date de publication:
06 07 2023
06 07 2023
Historique:
received:
01
02
2023
accepted:
17
05
2023
medline:
7
7
2023
pubmed:
6
7
2023
entrez:
5
7
2023
Statut:
epublish
Résumé
Following solid organ transplantation, tacrolimus (TAC) is an essential drug in the immunosuppressive strategy. Its use constitutes a challenge due to its narrow therapeutic index and its high inter- and intra-pharmacokinetic (PK) variability. As the contribution of the gut microbiota to drug metabolism is now emerging, it might be explored as one of the factors explaining TAC PK variability. Herein, we explored the consequences of TAC administration on the gut microbiota composition. Reciprocally, we studied the contribution of the gut microbiota to TAC PK, using a combination of in vivo and in vitro models. TAC oral administration in mice resulted in compositional alterations of the gut microbiota, namely lower evenness and disturbance in the relative abundance of specific bacterial taxa. Compared to controls, mice with a lower intestinal microbial load due to antibiotics administration exhibit a 33% reduction in TAC whole blood exposure and a lower inter-individual variability. This reduction in TAC levels was strongly correlated with higher expression of the efflux transporter ABCB1 (also known as the p-glycoprotein (P-gp) or the multidrug resistance protein 1 (MDR1)) in the small intestine. Conventionalization of germ-free mice confirmed the ability of the gut microbiota to downregulate ABCB1 expression in a site-specific fashion. The functional inhibition of ABCB1 in vivo by zosuquidar formally established the implication of this efflux transporter in the modulation of TAC PK by the gut microbiota. Furthermore, we showed that polar bacterial metabolites could recapitulate the transcriptional regulation of ABCB1 by the gut microbiota, without affecting its functionality. Finally, whole transcriptome analyses pinpointed, among others, the Constitutive Androstane Receptor (CAR) as a transcription factor likely to mediate the impact of the gut microbiota on ABCB1 transcriptional regulation. We highlight for the first time how the modulation of ABCB1 expression by bacterial metabolites results in changes in TAC PK, affecting not only blood levels but also the inter-individual variability. More broadly, considering the high number of drugs with unexplained PK variability transported by ABCB1, our work is of clinical importance and paves the way for incorporating the gut microbiota in prediction algorithms for dosage of such drugs. Video Abstract.
Sections du résumé
BACKGROUND
Following solid organ transplantation, tacrolimus (TAC) is an essential drug in the immunosuppressive strategy. Its use constitutes a challenge due to its narrow therapeutic index and its high inter- and intra-pharmacokinetic (PK) variability. As the contribution of the gut microbiota to drug metabolism is now emerging, it might be explored as one of the factors explaining TAC PK variability. Herein, we explored the consequences of TAC administration on the gut microbiota composition. Reciprocally, we studied the contribution of the gut microbiota to TAC PK, using a combination of in vivo and in vitro models.
RESULTS
TAC oral administration in mice resulted in compositional alterations of the gut microbiota, namely lower evenness and disturbance in the relative abundance of specific bacterial taxa. Compared to controls, mice with a lower intestinal microbial load due to antibiotics administration exhibit a 33% reduction in TAC whole blood exposure and a lower inter-individual variability. This reduction in TAC levels was strongly correlated with higher expression of the efflux transporter ABCB1 (also known as the p-glycoprotein (P-gp) or the multidrug resistance protein 1 (MDR1)) in the small intestine. Conventionalization of germ-free mice confirmed the ability of the gut microbiota to downregulate ABCB1 expression in a site-specific fashion. The functional inhibition of ABCB1 in vivo by zosuquidar formally established the implication of this efflux transporter in the modulation of TAC PK by the gut microbiota. Furthermore, we showed that polar bacterial metabolites could recapitulate the transcriptional regulation of ABCB1 by the gut microbiota, without affecting its functionality. Finally, whole transcriptome analyses pinpointed, among others, the Constitutive Androstane Receptor (CAR) as a transcription factor likely to mediate the impact of the gut microbiota on ABCB1 transcriptional regulation.
CONCLUSIONS
We highlight for the first time how the modulation of ABCB1 expression by bacterial metabolites results in changes in TAC PK, affecting not only blood levels but also the inter-individual variability. More broadly, considering the high number of drugs with unexplained PK variability transported by ABCB1, our work is of clinical importance and paves the way for incorporating the gut microbiota in prediction algorithms for dosage of such drugs. Video Abstract.
Identifiants
pubmed: 37408070
doi: 10.1186/s40168-023-01578-y
pii: 10.1186/s40168-023-01578-y
pmc: PMC10324113
doi:
Substances chimiques
Tacrolimus
WM0HAQ4WNM
Cytochrome P-450 CYP3A
EC 1.14.14.1
Immunosuppressive Agents
0
ATP Binding Cassette Transporter, Subfamily B
0
ATP Binding Cassette Transporter, Subfamily B, Member 1
0
Membrane Transport Proteins
0
Types de publication
Video-Audio Media
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
138Informations de copyright
© 2023. The Author(s).
Références
Transplant Rev (Orlando). 2015 Apr;29(2):78-84
pubmed: 25687818
Basic Clin Pharmacol Toxicol. 2010 Jun;106(6):505-10
pubmed: 20102364
Nature. 2021 Dec;600(7889):500-505
pubmed: 34880489
Drug Metab Dispos. 2015 Oct;43(10):1505-21
pubmed: 26261286
PLoS One. 2015 Mar 27;10(3):e0122399
pubmed: 25815766
Eur J Pharm Sci. 2006 Jul;28(4):291-9
pubmed: 16704924
Drug Metab Dispos. 1999 Jun;27(6):633-6
pubmed: 10348790
Drug Metab Dispos. 2009 Aug;37(8):1604-10
pubmed: 19460946
Drug Metab Dispos. 2013 Aug;41(8):1514-21
pubmed: 23686319
Clin Pharmacokinet. 1995 Dec;29(6):404-30
pubmed: 8787947
Drug Metab Dispos. 2019 Mar;47(3):194-202
pubmed: 30598508
Immunity. 2014 Aug 21;41(2):296-310
pubmed: 25065623
Drug Metab Dispos. 2017 Dec;45(12):1225-1238
pubmed: 28939687
J Cachexia Sarcopenia Muscle. 2021 Apr;12(2):456-475
pubmed: 33599103
Pharmacogenet Genomics. 2013 May;23(5):251-61
pubmed: 23459029
Am J Transplant. 2020 Aug;20(8):1969-1983
pubmed: 32406604
Gut. 2020 Aug;69(8):1510-1519
pubmed: 32409589
Nature. 2021 May;593(7857):147-151
pubmed: 33828301
Pharmacol Ther. 2015 May;149:1-123
pubmed: 25435018
Transplantation. 2014 Oct 15;98(7):697-705
pubmed: 25289916
Br J Clin Pharmacol. 2007 Dec;64(6):750-7
pubmed: 17425625
Am J Transplant. 2005 Jun;5(6):1383-91
pubmed: 15888045
PLoS One. 2017 May 24;12(5):e0178228
pubmed: 28542523
Cell Host Microbe. 2022 Jun 8;30(6):764-785
pubmed: 35679823
Am J Transplant. 2020 Sep;20(9):2413-2424
pubmed: 32243709
Front Microbiol. 2017 Nov 15;8:2224
pubmed: 29187837
Nature. 2015 Dec 10;528(7581):262-266
pubmed: 26633628
Cell. 2006 Aug 25;126(4):789-99
pubmed: 16923397
Am J Transplant. 2018 Jul;18(7):1646-1656
pubmed: 29316256
Am J Transplant. 2022 Mar;22 Suppl 2:21-136
pubmed: 35266618
Pharmacogenet Genomics. 2017 Sep;27(9):313-322
pubmed: 28704257
Pharmacogenomics. 2016 Jun;17(9):1019-27
pubmed: 27266721
Drug Metab Dispos. 1995 Jan;23(1):28-34
pubmed: 7536652
Cell. 2020 Jun 25;181(7):1661-1679.e22
pubmed: 32526207
PLoS One. 2014 Mar 12;9(3):e91555
pubmed: 24621983
Transplant Rev (Orlando). 2022 Jan;36(1):100668
pubmed: 34688985
Transplant Proc. 2005 Dec;37(10):4246-50
pubmed: 16387090
Nutr Metab Cardiovasc Dis. 2019 Apr;29(4):319-324
pubmed: 30782507
J Biol Chem. 1993 Mar 25;268(9):6077-80
pubmed: 7681059
Biopharm Drug Dispos. 2017 Mar;38(2):115-126
pubmed: 27516347
Nan Fang Yi Ke Da Xue Xue Bao. 2018 Dec 30;38(12):1401-1408
pubmed: 30613005
Drug Metab Dispos. 2023 Apr;51(4):509-520
pubmed: 36623881
mBio. 2011 Mar 01;2(2):e00271-10
pubmed: 21363910
Epilepsy Res. 2022 Jul;183:106925
pubmed: 35526327
Curr Med Chem. 2001 Jan;8(1):39-50
pubmed: 11172691
Mol Pharm. 2018 Dec 3;15(12):5711-5727
pubmed: 30388019
Microorganisms. 2020 Nov 04;8(11):
pubmed: 33158078
Clin Transplant. 2004 Oct;18(5):585-90
pubmed: 15344965
PLoS One. 2011 Mar 21;6(3):e17996
pubmed: 21445311
Pharmaceutics. 2021 Mar 15;13(3):
pubmed: 33804018
Nat Rev Microbiol. 2016 Apr;14(5):273-87
pubmed: 26972811
Transplant Proc. 2010 Jun;42(5):1870-2
pubmed: 20620540
Molecules. 2017 Sep 29;22(10):
pubmed: 28961159
Transplant Direct. 2019 Aug 23;5(9):e485
pubmed: 31579813
Gut. 2012 Aug;61(8):1124-31
pubmed: 22115825
Expert Opin Drug Metab Toxicol. 2020 Sep;16(9):769-782
pubmed: 32721175
mBio. 2022 Aug 30;13(4):e0199322
pubmed: 35968955
Appl Environ Microbiol. 1997 Sep;63(9):3367-73
pubmed: 9292986
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3369-74
pubmed: 11248085
Microbiome. 2021 Sep 7;9(1):183
pubmed: 34493329
Transplant Direct. 2020 Sep 17;6(10):e601
pubmed: 33134481
Anesthesiol Clin. 2017 Sep;35(3):365-380
pubmed: 28784214
World J Gastroenterol. 2018 Apr 28;24(16):1795-1802
pubmed: 29713132
Science. 2013 Nov 22;342(6161):967-70
pubmed: 24264989
Nature. 2019 Jun;570(7762):462-467
pubmed: 31158845
Xenobiotica. 2009 Apr;39(4):323-34
pubmed: 19350455